Ramelteon: a melatonin receptor agonist for the treatment of insomnia.
J Postgrad Med
;
2008 Jan-Mar; 54(1): 45-8
Article
in English
| IMSEAR
| ID: sea-115805
ABSTRACT
Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for the treatment of insomnia characterized by difficulty in sleep onset. It is a nonscheduled drug since it lacks the potential for abuse and does not interact with neurotransmitter receptors most associated with these phenomena. Although the effects of ramelteon use > 5 weeks are unknown, the available data confirms its safety and efficacy for short-term use. Clinical use and future research should uncover more information about ramelteon's properties.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Humans
/
Treatment Outcome
/
Receptors, Melatonin
/
Drug Interactions
/
Indenes
/
Sleep Initiation and Maintenance Disorders
Language:
English
Journal:
J Postgrad Med
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS